Axsome Therapeutics (NASDAQ:AXSM) Given New $238.00 Price Target at Piper Sandler

Posted by Geri Gentry on Oct 26th, 2026

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price reduced by stock analysts at Piper Sandler from $258.00 to $238.00 in a report issued on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler‘s price target would indicate a potential upside of 64.09% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Morgan Stanley lowered their price target on shares of Axsome Therapeutics from $251.00 to $247.00 and set an “equal weight” rating on the stock in a report on Friday, September 25th. Zacks Research raised shares of Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Guggenheim raised their price objective on shares of Axsome Therapeutics from $260.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Axsome Therapeutics in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $274.68.

View Our Latest Research Report on Axsome Therapeutics

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM opened at $145.04 on Monday. The business has a fifty day simple moving average of $191.71 and a 200 day simple moving average of $212.44. The company has a current ratio of 1.43, a quick ratio of 1.34 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of $7.60 billion, a price-to-earnings ratio of -38.68 and a beta of 0.86. Axsome Therapeutics has a one year low of $123.50 and a one year high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. The firm had revenue of $218.38 million during the quarter, compared to the consensus estimate of $221.11 million. Sell-side analysts expect that Axsome Therapeutics will post -2.97 EPS for the current year.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 10,000 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the transaction, the chief operating officer directly owned 10,000 shares in the company, valued at approximately $2,086,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Herriot Tabuteau sold 45,004 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $212.01, for a total transaction of $9,541,298.04. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $1,532,620.29. The trade was a 86.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 59,664 shares of company stock valued at $12,624,805. Insiders own 20.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AXSM. BlackRock Inc. acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth about $759,695,000. ABS Investment Management LLC acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at approximately $171,339,000. Bank of America Corp DE acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at approximately $110,756,000. First Trust Advisors LP boosted its stake in shares of Axsome Therapeutics by 1,230.2% during the 1st quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock worth $97,606,000 after acquiring an additional 534,066 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $55,171,000. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

(Get Free Report)

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.